SecBot SecBot
6-K ·Filed May 5, 2026

BNTX

BioNTech SE
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001776985-26-000030
Notable filing: 6-K
Actionable Insight ◆ Mixed

The Q1 results confirm the COVID-19 revenue decline trajectory is on track with guidance, but the widening net loss and CEO succession uncertainty create near-term overhang. The oncology pipeline catalysts (pumitamig Phase 2 data at ASCO, gotistobart Phase 3 interim, trastuzumab pamirtecan BLA filing) represent the primary value drivers for 2026. The $1.0B buyback provides a floor but does not offset fundamental deterioration. Monitor the May 29 ASCO data readout for pumitamig as a key inflection point.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$95.50
T+0 close · May 5, 2026 · via day close
Latest settled
−2.77%
T+60 · $92.85
Vs SPY
−5.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $95.50entry
  2. T+1 · 7mo ago −0.25%α −1.64% · $95.26
  3. T+5 · 6mo ago −1.93%α −3.91% · $93.66
  4. T+20 · 6mo ago −6.66%α −11.61% · $89.14
  5. T+60 · 4mo ago −2.77%α −5.51% · $92.85

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY from €182.8M) and a net loss of €531.9M (vs. €415.8M loss a year ago), driven by declining COVID-19 vaccine sales. The company reaffirmed FY2026 revenue guidance of €2.0-2.3B and announced a planned $1.0B share repurchase program, a manufacturing consolidation affecting ~1,860 positions, and multiple oncology pipeline catalysts including six late-stage data readouts expected in 2026. The co-founders will transition to a new independent company by end of 2026, triggering a CEO/CFO succession search.

Key Facts

  • Q1 2026 revenue of €118.1M, down 35.4% YoY from €182.8M
  • Q1 2026 net loss of €531.9M, widening from €415.8M loss in Q1 2025
  • Diluted loss per share of €2.10 (Q1 2025: €1.73)
  • Cash, cash equivalents and security investments of €16.8B as of March 31, 2026
  • FY2026 revenue guidance reaffirmed at €2.0-2.3B
  • Planned share repurchase program of up to $1.0B over twelve months
  • Manufacturing consolidation to exit sites in Idar-Oberstein, Marburg, Singapore and CureVac sites, affecting ~1,860 positions
  • Expected recurring annual cost savings of ~€500M by 2029 from manufacturing consolidation
  • Five additional pivotal trials for pumitamig initiated in Q1 2026 in collaboration with Bristol Myers Squibb
  • Six late-stage pipeline data readouts expected in 2026 across immunomodulators, ADC and mRNA programs
  • Co-founders Ugur Sahin and Ozlem Tureci to transition to new independent company by end of 2026; Supervisory Board initiated CEO/CFO succession search
  • Gotistobart Phase 3 data showed 54% reduction in risk of death vs docetaxel in squamous NSCLC
  • Trastuzumab pamirtecan BLA filing planned in 2026 for HER2-expressing endometrial cancer

Financial Impact

Revenue declined 35% YoY to €118.1M; net loss widened 28% to €531.9M; cash position remains strong at €16.8B; $1.0B buyback authorized; ~€500M annual cost savings targeted by 2029

revenuenet lossdiluted EPScash positionR&D expensesSG&A expenses

Risk Factors

  • Continued COVID-19 vaccine revenue decline faster than guided
  • CEO/CFO transition creates strategic uncertainty and potential talent drain
  • Oncology pipeline clinical trial failures or delays
  • Manufacturing consolidation execution risk and associated exit costs
  • Dilution from share repurchase program if not executed efficiently

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000030
Document: a992bntx1q2026presentati.htm0001776985-26-000030
Document: form6-kq12026earningsprear.htm0001776985-26-000030
Document: 0001776985-26-000030-index-headers.html0001776985-26-000030
Document: 0001776985-26-000030-index.html0001776985-26-000030
Document: 0001776985-26-000030.txt0001776985-26-000030

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (13h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026